On April 29, Novo Nordisk (NVO -5.41%) and Hims & Hers Health (HIMS -34.62%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on the news. It wasn't a marriage made in heaven. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers, and that direct access to Wegovy won't be available via NovoCare Pharmacy to Hims & Hers members. Here's what investors need to know about the implications of the termination of the short-li ...

智通财经APP获悉，在落后竞争对手礼来(LLY.US)数个月后，丹麦制药巨头诺和诺德(NVO.US)终于进 入印度这个全球人口第一大国。诺和诺德表示，将在印度销售其畅销的减肥药物Wegovy。该药物已在 印度获批用于长期慢性体重管理及降低重大心血管不良事件的风险。截至发稿，诺和诺德周二美股盘前 涨逾2%。 诺和诺德在周二发布的一份声明中表示，这种每周注射一次的药物(其活性成分为司美格鲁肽)将以五种 剂量销售。诺和诺德印度区董事总经理Vikrant Shrotriya表示，此次定价为"印度专属定价"，起始剂量 0.25毫克的售价为4336.25卢比(约合50.3美元)，而最高剂量2.4毫克的售价为6503.75卢比。 Vikrant Shrotriya表示，诺和诺德愿与保险公司和金融机构合作，提升该药物的可负担性和可及性，并将 在未来考虑与本地企业建立合作关系以进一步推广产品。 根据市场分析公司Pharmarack Technologies的数据，自礼来今年早些时候在印度推出Mounjaro以来，其 销量在5月份环比增长了60%。该公司表示，使用该药物的患者数量可能已翻倍，反映出印度民众对这 类疗法的浓厚兴趣。 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 司美格鲁肽 （Semaglutide） 是 诺和诺德 公司开发的一款 胰高血糖素样肽-1 （GLP-1） 受体激动剂， 能够抑制食欲，减少热量摄入， 已获批用于治疗 2 型 糖尿病以及减肥。 司美格鲁肽的出现，彻底颠覆了减肥药市场格局，今年一季度，其销售额超 78 亿美元。然而， 礼来 公司推出的 GLP-1/GIP 双受体激动剂 替尔泊肽 （Tizepatide） 刷新了司美格鲁肽创下的减重效果纪录，今年 5 月份， 《 新英格兰医学杂志 》 （NEJM） 发表的头对头临床试验 （ SURMOUNT-5 ） 结果 显示，替尔泊肽在 减轻体重 和 缩小腰围 方面的效果显著优于司美格鲁肽 【1】 ，在为期 72 周的治疗中，替尔泊肽治疗组患者平均减重 20.2% （减掉 22.8 公 斤） ，31.6% 的人减重 ≥ 25%。 更重要的是，替尔泊肽在今年一季度的销售额已超 61 亿美元，与司美格鲁肽的差距已不大。 2025 年 6 月 22 日，国际顶尖医学期刊 《 新英格兰医学杂志 》 （NEJM） 同期发表了两篇临床研究论文 【2、3】 ，这两项 3a 期临床试验，旨 ...

在流行减肥药的基础上增加一种试验性药物，或能解决使用者在快速减重过程中肌肉流失的关键痛点。 6月23日，美国糖尿病协会于芝加哥举行的会议上公布实验数据，礼来公司旗下的试验性药物 bimagrumab与诺和诺德的Wegovy联用，可帮助患者在48周内减轻22.1%的体重，其中高达92.8%的减 重来自脂肪。相比之下，单独使用Wegovy的患者体重减轻15.7%，脂肪减重占比仅为71.8%。 据媒体报道，该发现意味着，通过组合疗法，患者可以在实现有效减重的同时，最大限度地保留宝贵的 肌肉组织。肌肉流失一直是困扰快速减重人群，尤其是65岁以上老年用药者的主要担忧。周一美股收 盘，礼来公司股价一度涨近3.6%，随后回落收涨1%。 尽管前景光明，但药物组合疗法可能带来更多副作用的风险，也引起了一些医生的担忧。 在减肥药市场寻找立足点的再生元公司近期也曾表示，Wegovy与另外两种试验性药物的组合疗法，在 试验中同样促进了更多体重下降并有效保留了肌肉。然而，该试验中约有28%的患者中途退出，且有两 名接受药物的患者死亡。 尽管再生元称"尚未确定药物与死亡之间存在因果关系"，但据分析师称，这一结果"令人不安"。 风险提示及 ...

Core Viewpoint - The article highlights the deceptive marketing practices surrounding weight loss products, where seemingly genuine consumer experiences are actually orchestrated by businesses to lure customers into purchasing high-priced items [1][2]. Group 1: Marketing Tactics - Social media platforms are flooded with enticing weight loss posts that promise quick results, such as "lose 10 pounds in 15 days" [1]. - These posts are often created by businesses using fake accounts to simulate ordinary consumers, leading to a false sense of credibility [1]. - The marketing strategy exploits the common desire to lose weight without effort, promoting the idea of "effortless weight loss" [1]. Group 2: Health Risks - Many advertised weight loss products, claiming to be "purely plant-based" and "without side effects," may actually contain banned substances like sibutramine and phenolphthalein [2]. - Long-term use of these products can result in serious health issues, including metabolic disorders and heart diseases, with symptoms often appearing only after prolonged use [2]. - The rise of misleading weight loss narratives undermines public trust in scientific weight management and can lead to harmful health practices [2]. Group 3: Regulatory Concerns - There exists a gray industry behind these weight loss posts, characterized by professional "weight loss promoters" who are either hired by unscrupulous businesses or are fake influencers [2]. - The growth of this gray market reveals significant regulatory gaps, including inadequate platform oversight and weak accountability for false advertising [2]. - To combat this issue, regulatory bodies need to implement comprehensive review mechanisms and classify weight loss content under advertising regulations [3].

Core Insights - Novo Nordisk's new weight loss drug CagriSema shows promising results in weight reduction and metabolic improvement, but has a higher incidence of gastrointestinal side effects compared to the placebo group [1][2] - The company recently experienced a leadership change with the dismissal of CEO Lars Fruergaard Jorgensen [1] - CagriSema demonstrated an average weight loss of approximately 23% in overweight or obese non-diabetic patients and 15.8% in overweight patients with type 2 diabetes over a 68-week clinical trial [1] - The drug's efficacy data is comparable to Eli Lilly's Tirzepatide, which achieved a 22% weight loss in a 72-week trial [1] Safety and Side Effects - 79.6% of CagriSema users reported gastrointestinal reactions such as nausea, vomiting, and constipation, compared to 39.9% in the placebo group [2] - The incidence of serious adverse events was 9.8% in the CagriSema group, higher than the 6.1% in the placebo group, although most side effects were mild to moderate and transient [2] - 6% of CagriSema participants discontinued treatment due to adverse events, compared to 3.7% in the placebo group [2] Future Plans and Market Position - Novo Nordisk plans to submit a marketing application for CagriSema in Q1 2026, with expectations for approval in early 2027 [3] - The company is also conducting additional research on cardiovascular benefits beyond weight loss indications [3] - A flexible dosing adjustment strategy will be a key focus in clinical application, allowing for controlled weight loss rates while minimizing side effects [3] - The global obesity treatment market is highly competitive, and CagriSema will directly compete with Eli Lilly's GLP-1/GIP dual-target drug if successfully launched [3]

A股午评：三大股指走势分化 白酒股领跌大盘 金十数据6月23日讯，A股三大股指早盘集体低开，盘初一度冲高随后走势分化，沪指维持涨势，深证 成指、创业板指回落转跌，截至中午收盘，沪指涨0.15%，深证成指跌0.16%，创业板指跌0.33%；沪深 两市半日成交额超6700亿，超3400只个股飘红。盘面上，石油股、军工股、能源金属板块领涨大盘，银 行股反弹，工商银行等多股再创新高，白酒股领跌大盘，贵州茅台午盘收跌0.46%，CPO概念、游戏、 减肥药等板块跌幅居前。 ...

Core Insights - The 85th American Diabetes Association (ADA) conference showcased innovative metabolic drugs, particularly focusing on weight loss medications, with GLP-1 agonists being a prominent research area [1][2] - Novo Nordisk reported that a higher dose of Wegovy (semaglutide 7.2 mg) resulted in an average weight reduction of 21% for obesity patients, with one-third of participants losing 25% or more of their body weight [1][4] - The competitive landscape includes multiple companies, with Novo Nordisk leading in the number of obesity drug pipelines, followed by Eli Lilly and several domestic firms [1][6] Company Developments - Novo Nordisk's STEP UP trial demonstrated significant weight loss effects with the higher dose of semaglutide, maintaining safety profiles consistent with existing GLP-1 medications [2][4] - Eli Lilly announced positive results for its oral small molecule GLP-1 receptor agonist, Orforglipron, showing significant reductions in A1C levels and an average weight loss of 7.3 kg in the highest dose group [5] - Novo Nordisk plans to submit a label update for the higher dose of Wegovy in the EU by mid-2025, while Eli Lilly aims to submit Orforglipron for weight management approval by the end of this year [4][5] Industry Trends - The focus on innovative mechanisms for weight loss drugs includes long-acting, oral, multi-target, and muscle-preserving approaches, indicating a shift towards more effective treatment options [6][8] - The dual and triple-target GLP-1 agonists are gaining traction, with Eli Lilly's Retatrutide leading in global development, while several Chinese companies are advancing their products into clinical phases [7][8] - The market is seeing a growing number of combination therapies, with 13 dual-target and 9 multi-target combinations currently in development, totaling 88 related investigational drugs [7]

中国生物技术公司杭州先为达生物科技有限公司开发的肥胖治疗药物埃诺格鲁肽（ecnoglutide）在III期 临床试验中展现出强劲表现，48周治疗后患者平均减重超过15%。这一成果标志着中国在全球减肥药市 场竞争中迈出重要一步，礼来和诺和诺德的"王牌减肥产品"或将迎来劲敌。 据最新公开消息，埃诺格鲁肽注射液治疗中国超重或肥胖患者的3期临床试验（SLIMMER）由北京大 学人民医院纪立农教授团队牵头开展，研究成果于当地时间6月21日在第85届美国糖尿病协会（ADA） 学术会议上以口头报告发布，且全文同步在线发表在国际顶级医学期刊《柳叶刀-糖尿病与内分泌学》 （The Lancet Diabetes & Endocrinology）。 减重15.1% 比肩国际一流 据医药魔方Pro报道，SLIMMER研究是目前中国最大样本量的减重药物Ⅲ期临床试验，在全国 36 个中 心入组 664 例肥胖（BMI≥28kg/m²）或超重（BMI≥24kg/m²）且伴有至少一种体重相关合并症的患者， 随机接受每周一次埃诺格鲁肽 1.2mg、1.8mg、2.4mg 或安慰剂治疗 48 周。 第 48 周时，2.4mg 剂量组体重较基线 ...

吃饭前一定要先查阅食材热量，饮料要喝零卡无糖的，哪怕运动也要仔细计算出消耗的卡路里……这种 计算卡路里的狂热，正在社交媒体上成为流行。 此类风潮，来源于减肥最底层的逻辑：摄入热量要少于消耗热量，制造热量缺口。 然而，减肥并不是简单的数字计算。 2018年一项来自斯坦福大学的研究曾证明，痴迷地计算卡路里并不是削减腰围的关键。研究人员监测了 600多名超重成年人的饮食。尽管受试者没有专注于减少卡路里，但基于低脂或低碳饮食，他们在一年 中平均减掉了约12磅。 对食物而言，热量实际上只是与之相关的极小部分。当我们把食物简化成一个个数字，反而切断了我们 与食物的内在联系。 与其在严格的计算中增加焦虑，相信自己身体的信号，聚焦于吃什么而非吃的热量，或许才是减肥更优 的方式。 当代减脂人困在卡路里、数值里 每次吃饭前，阿诺必须要打开自己的卡路里计算app。 减肥三个月，她每天都要保证自己的摄入量在2000大卡以内，以实现热量缺口。 一方面，严格的数值计算往往带来更大的心理压力，反而更容易导致暴饮暴食。 另一方面，卡路里这一概念本身的计算方法与人体对热量的吸收原理并不一致。而食物之间的热效应差 异更会导致即使是同样卡路里的不 ...